Mark G. Kris, MD
Chief, Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, NY
Fred R. Hirsch, MD, PhD
Professor of Medicine and Pathology
Division of Medical Oncology
University of Colorado
M. Blair Marshall, MD, FACS
Chief, Division of Thoracic Surgery
Department of Surgery
Georgetown University Hospital
Minesh P. Mehta, MD, FASTRO
Professor, Radiation Oncology
Feinberg School of Medicine
Estimated amount of time to complete: 1 hour
Virtual Tumor Board
Lung cancer is the leading cause of worldwide cancer mortality and is responsible for more deaths annually in the U.S. than the combination of breast, colorectal, and prostate cancer. About 87% of lung cancer cases in the U.S. are classified as non-small cell lung cancer (NSCLC), and most cases are diagnosed at an advanced stage resulting in poor overall survival for most patients. Advanced NSCLC is incurable, and thus the goal of therapy is not only to improve survival times, but also to assure the best quality of life possible. Recently, treatment for advanced NSCLC has expanded beyond using chemotherapy as the cornerstone of treatment to include a new generation of targeted therapies that disrupt the cellular pathways involved in tumor growth, progression, and cell death.
The use of molecularly targeted therapies represents a significant advancement in the NSCLC treatment. However, the emergence of novel drugs and new treatment approaches make treatment for advanced NSCLC increasingly challenging. For this reason, tumor boards are all the more critical when making treatment decisions in advanced NSCLC. The multidisciplinary approach resulting from tumor boards ensures that all patient factors and tumor characteristics are considered for optimal treatment strategies and patient outcomes. This activity utilizes a virtual tumor board to provide a thorough discussion of a NSCLC case from various provider perspectives in order to communicate the most important advances in NSCLC care.
Medical, surgical, and radiation oncologists; pathologists; and other health care professionals interested or involved in the treatment of patients with NSCLC.
Upon completion of this educational activity, the participant should be able to:
Develop tailored treatment plans spanning all treatment sub-specialties for patients with advanced NSCLC.
Discuss how advances in the understanding of the molecular biology of advanced NSCLC influence treatment decisions.
Describe recent advances in the use of predictive biomarkers in advanced NSCLC.
Explore the role of emerging strategies for the treatment of NSCLC.
It is the policy of Temple University School of Medicine; The Albert J. Finestone, MD Office for Continuing Medical Education to insure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty, program planning committee members, and Temple University School of Medicine Continuing Medical Education staff participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).
PLANNING COMMITTEE DISCLOSURE STATEMENT
Planning committee members have no financial relationships to disclose.
FACULTY DISCLOSURE STATEMENT
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Dr. Kris discloses that he is a consultant to Pfizer, Boehringer Ingelheim, and Chugai.
Dr. Hirsch discloses that he is a consultant to OSI/Genentech/Roche, Boehringer Ingelheim, GSK, Celgene, ImClone/Lilly; and receives grant funding (via University of Colorado) from AstraZeneca, OSI, Syndax, ImClone, and Ventana.
Dr. Marshall discloses that she receives research funding from Thoracic Surgery Foundation for Research and Education-Stimulation Grant; and has submitted a patent application for a suture training device.
Dr. Mehta discloses that he a consultant to Schering, Merck, Genentech, TomoTherapy; is on a speakers' bureau for Schering; and holds stock in Pharmacyclics and TomoTherapy.
Accreditation Statement: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.
Certification Statement: Temple University School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee to participate and receive credit.
Credit Provider Contact Information
School of Medicine
The Albert J. Finestone, MD Office for CME
3500 North Broad Street Philadelphia, PA 19140
Commercial Support Statements
This activity is supported through an educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.
This activity is supported through an educational grant from
Genentech BioOncology. Instructions
Minimum System Requirements:
• Pentium III, 600 MHz or Equivalent Processor
• 512 MB of RAM
• Windows XP, Vista, or 7
• Mac OS X
• 800x600 Monitor Resolution
• 16-bit Color
• 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. You may start as a GUEST, but to claim credit, you must be a member. If you are not already registered as a user of this website, visit the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 60 minutes to complete.
After the program has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. A credit statement/certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.
Copyright © 2011. Temple University School of Medicine. All rights reserved.
Presented by Temple University School of Medicine and Medical Communications Media, Inc.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Temple University School of Medicine, Boehringer Ingelheim Pharmaceuticals, Inc, or Genentech BioOncology. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
To view our privacy policies, please visit: http://www.cmecorner.com/privacy.asp